STAT+: Moderna’s mRNA cancer vaccine shows promise in combination with melanoma drug
ORLANDO, Fla. — For years, early experimental results offered hope that scientists might be able to offer cancer vaccines tailored to an individual’s tumor as a treatment. On Sunday, a personalized mRNA cancer vaccine made by Moderna provided the first evidence that the approach can truly offer clinical benefit to patients.
The vaccine, called a neo-antigen cancer vaccine, greatly reduced a patient’s risk of relapse when combined with the Merck immunotherapy drug pembrolizumab (Keytruda) than when the drug was given alone.
